Farnesoid X receptor targeting for hepatitis C: Study protocol for a proof-of-concept trial;Ciblage du recepteur nucleaire des acides biliaires dans l'hepatite C : protocole d'un essai de validation de principe

Therapie

Volumn 67, Issue 5, 2012, Pages 423-427

  Scholtes, Caroline ^a,b,c   André, Patrice ^a,b,c   Trépo, Christian ^a   Cornu, Catherine ^c,d,f   Remontet, Laurent ^e,f   Ecochard, René ^e,f   Bejan Angoulvant, Theodora ^c,d,f   Gueyffier, François ^c,d,f  

^a CROIX ROUSSE HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c INSERM   (France)

^d LOUIS PRADEL HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f CNRS   (France)

Author keywords

Clinical trial; Farnesoid X receptor; Hepatitis C; Proof of concept

Indexed keywords

FARNESOID X RECEPTOR; GUGGULSTERONE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FRANCE; GENE TARGETING; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECEPTOR GENE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 84871386407     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2012058     Document Type: Article

References (16)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47
2. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72 (Pubitemid 41191673)
3. Rosen HR. Chronic Hepatitis C Infection. New Engl J Med 2011; 364: 2429-38
4. Sarrazin C, Kieffer TL, Bartels D et al. Hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-77 (Pubitemid 46677938)
5. Negro F, Sanyal AJ. Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver Int 2009; 29 Suppl 2: 26-37
6. Andre P, Komurian-Pradel F, Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-28 (Pubitemid 41246207)
7. Merz A, Long G, Hiet MS et al. Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. JBC 2011; 286: 3018-32
8. Nielsen SU, Bassendine MF, Burt AD et al. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-28 (Pubitemid 43271547)
9. Bradley D, McCaustland K, Krawczynski K et al. Hepatitis C virus: buoyant density of the factor VIII-derived isolate in sucrose. J Med Virol 1991; 34: 206-8
10. Jorquera F, Monte MJ, Guerra J et al. Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 547-54 (Pubitemid 40755266)
11. Scholtes C, Diaz O, Icard V et al. Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR. J Hepatol 2008; 48: 192-9
12. Szapary PO, Wolfe ML, Bloedon LT et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003; 290: 765-72 (Pubitemid 37432953)
13. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-7 (Pubitemid 28471138)
14. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford University Press. 1994
15. Pinheiro J, Bates D. Mixed-effects models in S and S-Plus. New York. Springer, 2000
16. Goodwin B, Gauthier KC, Umetani M et al. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci U S A 2003; 100: 223-8 (Pubitemid 36078056)